Gritstone Bio (NASDAQ: GRTS)
Some price data may be temporarily unavailable.
Gritstone Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gritstone Bio Company Info
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
News & Analysis
2 Beaten-Down Biotech Stocks That Could Make You Filthy Rich
These unloved biotechs have enormous upside potential.
Which Vaccine Stocks Will Make You a Fortune in 2022?
It's not too late to invest in this dynamic area.
Does This Biotech Have the Secret to Conquering Covid Variants?
The company uses mRNA technology -- with a new twist.
3 Explosive Biotech Stocks That Could 10X in 10 Years
They're leaders in therapeutic areas with massive growth potential.
3 Things to Consider Before You Buy Coronavirus Vaccine Stocks
Investing in vaccine stocks today is different than it was a year ago.
Is This Under-the-Radar COVID Stock the Next Moderna?
The coronavirus presents one big risk in the future. This vaccine maker is tackling it.
Why Gritstone Oncology Is Bolting Higher Today
Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.
Why Gritstone Oncology Stock Is Sinking Today
The pricing of a secondary stock offering is taking a toll on the biotech stock.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.